Xeris Biopharma Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
XERS$15.86+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements Consolidated Balance Sheets as of December 31, 202 and December 31, 2024
Consolidated Balance Sheets
(in thousands, except share and par value)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $111,042 | $71,621 |
| Trade accounts receivable, net | 51,050 | 40,415 |
| Inventory, net | 68,673 | 48,175 |
| Prepaid expenses and other current assets | 9,548 | 7,451 |
| Total current assets | 240,313 | 167,662 |
| Property and equipment, net | 4,945 | 5,562 |
| Operating lease right-of-use assets | 22,112 | 22,649 |
| Goodwill | 22,859 | 22,859 |
| Intangible assets, net | 88,078 | 98,921 |
| Other assets | 5,220 | 5,407 |
| Total assets | $383,527 | $323,060 |
| Liabilities and Stockholders' Equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $3,076 | $2,290 |
| Current portion of long-term debt | — | 15,102 |
| Current operating lease liabilities | 6,232 | 6,080 |
| Other accrued liabilities | 33,155 | 27,716 |
| Accrued trade discounts and rebates | 43,253 | 29,084 |
| Accrued returns reserve | 18,969 | 19,082 |
| Other current liabilities | 4,889 | 1,089 |
| Total current liabilities | 109,574 | 100,443 |
| Long-term debt, net of current portion and unamortized debt issuance costs | 220,335 | 217,006 |
| Non-current operating lease liabilities | 31,531 | 33,259 |
| Other liabilities | 8,398 | 1,967 |
| Total liabilities | 369,838 | 352,675 |
| Commitments and contingencies (Note 14) | ||
| Stockholders' equity (deficit): | ||
| Preferred stock—par value $0.0001, 25,000,000 shares and 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock—par value $0.0001, 350,000,000 shares and 350,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 166,215,410 and 149,429,410 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 17 | 15 |
| Additional paid in capital | 685,004 | 642,256 |
| Accumulated deficit | (671,307) | (671,861) |
| Accumulated other comprehensive loss | (25) | (25) |
| Total stockholders' equity (deficit) | 13,689 | (29,615) |
| Total liabilities and stockholders' equity (deficit) | $383,527 | $323,060 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.